Literature DB >> 9297066

[Viral load--significance for individualized therapy].

H Jäger1.   

Abstract

The treatment of HIV infection/AIDS has changed dramatically because of a new pathophysiological understanding of this disease. The most important laboratory parameter for the management of antiretroviral therapy is the direct measurement of virus load in plasma. In Germany 11 different medications are available to the patient for reduction of his viral load in blood and possibly tissues, i.e. lymph-nodes. The majority (about 2/3) of physicians begin to treat with double combination therapy. Protease inhibitors are an important addition to the therapeutic arsenal.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9297066     DOI： 10.1007/BF03044775

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


  14 in total

1.  ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Authors:  M F Para; P Meehan; J Holden-Wiltse; M Fischl; G Morse; R Shafer; L M Demeter; K Wood; T Nevin; N Virani-Ketter; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

3.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

4.  Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma.

Authors:  R L Dewar; H C Highbarger; M D Sarmiento; J A Todd; M B Vasudevachari; R T Davey; J A Kovacs; N P Salzman; H C Lane; M S Urdea
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

5.  Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia.

Authors:  C E Bush; R M Donovan; N Markowitz; D Baxa; P Kvale; L D Saravolatz
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

8.  Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load.

Authors:  R E Dickover; E M Garratty; S A Herman; M S Sim; S Plaeger; P J Boyer; M Keller; A Deveikis; E R Stiehm; Y J Bryson
Journal:  JAMA       Date:  1996-02-28       Impact factor: 56.272

9.  The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.

Authors:  A Ruffault; C Michelet; C Jacquelinet; O Guist'hau; N Genetet; C Bariou; R Colimon; F Cartier
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-07-01

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.